15.68
-0.70%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sansure Biotech
Its shares trade on Shanghai under the ticker 688289.SS. It has been listed since 28 August 2020. In the fiscal year to 31 December 2025, it reported net income of CN¥198.1m. At that date it held total assets of CN¥9.53bn and shareholders' equity of CN¥7.22bn.
Sansure Biotech, Inc. engages in the research, development, production, and sales of diagnostic reagents and instruments. The company is headquartered in Changsha, Hunan. The company went IPO on 2020-08-28. The firm's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The firm also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 28 Aug 2020
- Employees
- 2,567
- Website
- sansure.com.cn ↗
Leadership
Pay as last reported
- Mr. Lizhong DaiChairman of the Board, General Manager, since 2019CN¥700,600
- Mr. Zhu PengChief Financial Officer, Deputy General Manager, Director, since 2019CN¥1.7m
- Mr. Peng YinSenior Vice President, Chief Technology Officer, Deputy General ManagerCN¥2.3m
- Mr. Jia LiuDeputy General Manager, Director, since 2021CN¥557,800
- Mr. Xialin YuDeputy General Manager, Director, since 2019CN¥439,700
- Mr. Zhongping DengDeputy General ManagerCN¥522,600
- Mr. Zheng LianDeputy General Manager
- Mr. Kai LiuDeputy General ManagerCN¥1.6m
- Mr. Haixiao WangDeputy General ManagerCN¥1.4m
- Ms. Xiaoyan XiongDeputy General ManagerCN¥621,600
- Ms. Jun ZhouDeputy General ManagerCN¥970,400
- Mr. Jian ZhuDeputy General ManagerCN¥2.3m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 99
- Social
- 78
- Governance
- 21
- Direct emissions (scope 1)
- 128.34 t
- Energy emissions (scope 2)
- 6,933.59 t
- Women in the workforce
- 49.44587%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sansure Biotech employs 2567 employees in Changsha, Hunan for diagnostic reagent production.
- The company offers viral hepatitis series and reproductive tract infection products in Health Care sector.
- Sansure Biotech provides automatic nucleic acid detection systems and PCR monitoring software for medical use.
Weaknesses
- Sansure Biotech's diagnostic reagents are limited to viral hepatitis and reproductive tract infection segments.
- The company's instrument products lack diversity beyond nucleic acid detection systems.
- Sansure Biotech's services are restricted to medical institutions in Changsha, Hunan.
Opportunities
- Expanding diagnostic reagents to pediatric infection series in Health Care sector could increase market share.
- Growing demand for nucleic acid blood screening series in China presents new opportunities.
- The firm can leverage its PCR monitoring software for broader scientific research applications.
Threats
- Rising competition in the Health Care sector may impact Sansure Biotech's market position.
- Regulatory changes in China could affect diagnostic reagent approvals.
- Economic downturns in Hunan might reduce demand for medical inspection services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.